ProQR Therapeutics (PRQR) EBIT Margin (2021 - 2025)
ProQR Therapeutics recorded quarterly EBIT Margin of 194.05% in Q4 2025, up 50.44% quarter-over-quarter from 391.53% in Q3 2025, and up 4001.0% year-over-year from 4.73% in Q4 2024.
ProQR Therapeutics' EBIT Margin history runs 5 years deep, the most recent figure standing at 194.05% for Q4 2025.
- In Q4 2025, EBIT Margin rose 4001.0% year-over-year to 194.05%; the TTM figure through Dec 2025 stood at 273.87% (down 11251.0% YoY), while the FY2025 annual figure was 273.14%, down 11196.0% from the prior year.
- EBIT Margin came in at 194.05% for Q4 2025 at ProQR Therapeutics, up from 391.53% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 57.1% in Q2 2024 to a low of 7250.21% in Q4 2021.
- A 5-year average of 1393.14% and a median of 539.49% in 2023 frame the typical range for EBIT Margin.
- On a YoY basis, EBIT Margin climbed as much as 551965 bps in 2022 and fell as far as 76588 bps in 2022.
- ProQR Therapeutics' EBIT Margin stood at 7250.21% in 2021, then surged by 76 bps to 1730.56% in 2022, then surged by 89 bps to 190.86% in 2023, then fell by 23 bps to 234.06% in 2024, then advanced by 17 bps to 194.05% in 2025.
- According to Business Quant data, EBIT Margin over the past three periods registered 194.05%, 391.53%, and 320.91% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | -194.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -194.05% |
| Sep 30, 2025 | -391.53% |
| Jun 30, 2025 | -320.91% |
| Mar 31, 2025 | -239.34% |
| Dec 31, 2024 | -234.06% |
| Sep 30, 2024 | -226.80% |
| Jun 30, 2024 | -57.10% |
| Mar 31, 2024 | -181.46% |
| Dec 31, 2023 | -190.86% |
| Sep 30, 2023 | -539.49% |
| Jun 30, 2023 | -731.20% |
| Mar 31, 2023 | -1,433.44% |
| Dec 31, 2022 | -1,730.56% |
| Sep 30, 2022 | -2,435.26% |
| Jun 30, 2022 | -1,702.37% |
| Mar 31, 2022 | -1,508.32% |
| Dec 31, 2021 | -7,250.21% |
| Sep 30, 2021 | -1,669.38% |
| Jun 30, 2021 | -5,433.33% |